Which statement accurately explains how verapamil assists to correct an arrhythmia?

Verapamil is a Class IV antiarrhythmic and a non-dihydropyridine calcium channel blocker. It primarily targets the slow calcium channels in the atrioventricular node, which effectively slows the rate of depolarization and increases the refractory period, making it highly effective for controlling the ventricular rate in supraventricular tachycardias. A. Verapamil works by inhibiting the inward flow of calcium ions across the cell membranes of myocardial and vascular smooth muscle cells. In the heart, this specifically slows conduction through the AV node, which is essential for interrupting re-entrant circuits and slowing the heart rate during atrial fibrillation or flutter. B. While calcium channel blockers can have a mild effect on the sinoatrial node, verapamil's primary therapeutic mechanism for correcting arrhythmias is its potent inhibitory effect on the atrioventricular node. It is not primarily used to "alter" the initial sinus impulse, but rather to control the conduction of that impulse. C. Verapamil decreases, rather than increases, the speed and strength of the electrical impulse as it passes through the AV node. By slowing this conduction, the drug allows for a more controlled ventricular response, which is the desired therapeutic effect in the management of rapid atrial rhythms. D. Verapamil does not "desensitize" the heart to electrical impulses. Instead, it physically blocks the ion channels required for the electrical signal to propagate through the specialized conduction tissue. This is a mechanical blockade of ion movement rather than a change in the sensitivity of the cardiac tissue.